U.S. Contraceptive Market Size, Share, Growth Analysis, By Product(Pills, Intrauterine Devices (IUD) (Hormonal IUD), By Age-group(15-44 years, above 44 years), By End-User(Households, clinics) - Industry Forecast 2023-2030

To subscribe with us, please complete the form below.

What people say about us!

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

License Type Top market research company in USA

File Type

Analyst Support

$3,500

BUY NOW GET SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

SPEAK TO AN ANALYST

FAQ's

US Contraceptive Market size was valued at USD 7.88 billion in 2021 and is poised to grow from USD 8.3 billion in 2022 to USD 12.15 billion by 2030, growing at a CAGR of 5.16% in the forecast period (2023-2030).

Attributed to the existence of multiple enterprises, the global market is very competitive. Most businesses are pursuing strategic initiatives, such as R&D spending, in order to produce innovative goods and acquire a competitive advantage over rivals. High expenditures by well-known corporations in the commercialization of effective and long-term reversible contraception have raised public awareness of these products. 'Bayer AG', 'Pfizer Inc.', 'Merck & Co., Inc.', 'Allergan plc', 'Teva Pharmaceutical Industries Ltd.', 'Mylan N.V.', 'Church & Dwight Co., Inc.', 'Reckitt Benckiser Group plc', 'CooperSurgical, Inc.', 'Medicines360', 'Agile Therapeutics, Inc.', 'Afaxys, Inc.', 'HRA Pharma', 'TherapeuticsMD, Inc.', 'Apothecus Pharmaceutical Corporation', 'Mayer Laboratories, Inc.', 'The Female Health Company', 'Lumara Health Inc.', 'Veru Inc.', 'The Population Council, Inc.'

The introduction of more effective male contraception products is expected to boost contraceptive sales. Female contraceptives are currently the market leaders, but male contraceptives will see increased demand due to the increased use of male condoms.

During the projection period, development, approval, and commercialization of novel, more effective, and long-acting reversible contraceptive techniques are likely to boost the market growth. Agile Therapeutics, for example, created Twirla, a hormonal patch that will be available in the United States in the fourth quarter of 2020. The availability of generic and low-cost medications and technologies has increased the need for contraception among teens. Furthermore, nonhormonal contraceptives are becoming increasingly popular in the United States since they reduce the danger of undesirable consequences linked with hormonal imbalance in the body. In 29 states, insurers must provide comprehensive coverage for FDA-approved contraceptive methods for women. Over-the-counter contraceptives are covered in 12 states; however, insurers may require a prescription from the beneficiary. In 20 states and the District of Columbia, insurers are required to cover a large number of contraceptives at once.

Feedback From Our Clients

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

U.S. Contraceptive Market Size, Share, Growth Analysis, By Product(Pills, Intrauterine Devices (IUD) (Hormonal IUD), By Age-group(15-44 years, above 44 years), By End-User(Households, clinics) - Industry Forecast 2023-2030

To subscribe with us, please complete the form below.

What people say about us!

Want to customize this report?

FAQ's

What is the global market size of U.S. Contraceptive Market?

Who are the key vendors in the U.S. Contraceptive Market?

What is the key driver of U.S. Contraceptive Market?

What is the key market trend for U.S. Contraceptive Market?

Which region accounted for the largest share in U.S. Contraceptive Market?

Related Reports

Feedback From Our Clients

$3,500